BeyondSpring Inc.
BYSI evidence brief
What we can confirm
- BioSniper Score:
- 4.6 / 10
- Market Cap:
- $32.0M
- Lead Asset:
- Plinabulin (Phase 3)
What it means
What to watch
Prepared research question
What matters most for BYSI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BYSI
BeyondSpring Inc. (BYSI) is a clinical-stage biotech focused on plinabulin, a microtubule-binding agent for non-small cell lung cancer, with a recent FDA Fast Track designation and a strategic transaction for the asset.
Key risk: Low cash runway
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$32.0M
Cash Runway
—
Lead Asset
Plinabulin (Phase 3)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 1 clinical trial for BeyondSpring Inc..
BeyondSpring Inc. (BYSI) is a clinical-stage biotech focused on plinabulin, a microtubule-binding agent for non-small cell lung cancer, with a recent FDA Fast Track designation and a strategic transaction for the asset.
- Lead candidate plinabulin is in Phase 3 for non-small cell lung cancer as a selective immunomodulating microtubule-binding agent [pipeline].
- Cash & equivalents were $2.7M as of 2026-06-30, with zero revenue and a net loss of $0.8M for the period [sec].
- FDA granted Fast Track designation for plinabulin in post-ICI non-squamous NSCLC as of September 2026 [news · published 2026-09-29].
- ASCO 2026 data showed a long-term survival benefit of plinabulin/docetaxel and pembrolizumab in metastatic NSCLC after progression on first-line ICI therapy [news · published 2026-08-14].
- AACR 2026 preclinical data positioned plinabulin as a potential backbone agent to combine with ADC regimens [news · published 2026-05-13].
What works
- Plinabulin has completed a Phase 3 trial (DUBLIN-3) showing a statistically significant median OS improvement (10.5 vs 9.4 months, p=0.0399) [catalyst].
- The company has secured FDA Fast Track designation for plinabulin in a specific NSCLC indication, which may expedite development and review [news · published 2026-09-29].
- Preclinical data suggest plinabulin could be combined with ADC therapies, potentially broadening its application [news · published 2026-05-13].
What to weigh
- Cash position is very low at $2.7M as of 2026-06-30, with no revenue and a negative shareholders' equity of -$35.6M [sec].
- The company reported a net loss of $0.8M for the period ending 2026-06-30, indicating ongoing cash burn without product revenue [sec].
- Plinabulin faces competition from PD-1/PD-L1 antibodies, ADCs, and docetaxel in the NSCLC space [pipeline].
- The Phase 3 OS benefit, while statistically significant, was modest (1.1 months median improvement) [catalyst].
From the filings
Quoted directly from source documents.
Plinabulin is a selective immunomodulating microtubule-binding agent in Phase 3 for NSCLC
“Pipeline Candidate: Plinabulin Generic Name: Plinabulin Indication: Non-Small Cell Lung Cancer Phase: Phase 3 Mechanism of Action: Selective Immunomodulating Microtubule-Binding Agent (SIMBA) that depolymerizes microtubules, activates GEF-H1, and induces dendritic cell maturation”
Phase 3 DUBLIN-3 trial showed a median OS of 10.5 vs 9.4 months (p=0.0399)
“Median OS was 10·5 months (95% CI 9·34-11·87) in the plinabulin group compared with 9·4 months (8·38-10·68) in the control group (stratified HR 0·82, 95% CI 0·68-0·99; p=0·0399).”
Catalysts · October 31, 2024
FDA Fast Track designation for plinabulin in post-ICI non-squamous NSCLC
“BeyondSpring Inc. (BYSI) Discusses FDA Fast Track Designation and Strategic Transaction for Plinabulin in Post-ICI Non-Squamous NSCLC”
News · September 29, 2026
Catalyst timeline
- 2024-10-31 · Trial_Readout: Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial. — Phase 3 readout showed a statistically significant but modest median OS improvement of 1.1 months.
Risks & what to watch (4)›
Key risks
- Low cash runway — Cash of $2.7M as of 2026-06-30 with no revenue and a net loss of $0.8M suggests limited operating runway [sec].
- Negative shareholders' equity — Shareholders' equity was -$35.6M as of 2026-06-30, indicating accumulated losses exceed capital [sec].
- Modest Phase 3 OS benefit — Median OS improvement of 1.1 months in DUBLIN-3 may limit commercial differentiation vs competitors [catalyst].
- Competitive landscape — Plinabulin competes with PD-1/PD-L1 antibodies, ADCs, and docetaxel in NSCLC [pipeline].
What to watch
- Outcome of the strategic transaction for plinabulin discussed in September 2026 [news · published 2026-09-29].
- Next clinical readouts from plinabulin combination studies with ADCs or pembrolizumab [news · published 2026-08-14].
- Cash position updates in future quarterly filings to assess runway [sec].
- Any regulatory milestones following the Fast Track designation [news · published 2026-09-29].
Sources: Catalysts · Competitor trials · News · Pipeline · Generated October 12, 2026 · How we verify sources →
Run BeyondSpring Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BeyondSpring Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$849K
Lead: Phase 3
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 6.4%
- Days to cover
- 224.7
- Shares short
- 2,188,849
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BYSI short interestFrequently asked questions
What is the AI investment thesis for BeyondSpring Inc.?
BeyondSpring Inc. (BYSI) is a clinical-stage biotech focused on plinabulin, a microtubule-binding agent for non-small cell lung cancer, with a recent FDA Fast Track designation and a strategic transaction for the asset.
What is BeyondSpring Inc.'s lead drug candidate?
BeyondSpring Inc.'s most advanced tracked candidate is Plinabulin (Phase 3) for Non-Small Cell Lung Cancer.
Who is the CEO of BeyondSpring Inc.?
Mr. Min Qiu is the chief executive officer of BeyondSpring Inc. (BYSI).
Where is BeyondSpring Inc. headquartered?
BeyondSpring Inc. (BYSI) is headquartered in Florham Park, NJ, United States.
What therapeutic areas does BeyondSpring Inc. focus on?
BeyondSpring Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.